Advertisement

HCC Radioembolization with Yttrium-90 Glass Microspheres (TheraSphere)

  • Marco Maccauro
  • Gianluca Aliberti
  • Carlo Chiesa
  • Carlo Spreafico
Chapter

Abstract

Intraarterial radioembolization (RE) using microspheres labelled with the high-energy beta-emitter yttrium-90 (90Y) is an innovative local therapy for hepatocellular carcinoma (HCC). This procedure allows the tumour to be irradiated with a dose higher than that allowed by whole-liver external beam radiation treatment. The TheraSphere (TheraSphere_BTG®) consist of glass microspheres labelled with 90Y as an integral component of glass. The mean diameter of glass sphere is 20–30 μm, and a high specific activity per sphere at calibration is 2500 Bq. The recommended TheraSphere® Dose to the hepatic lobe is 120 Gy (80–150 Gy). It is possible to choose 35 dose size options, between 3 GBq and 20 GBq in 0.5 GBq increments, a dosing flexibility and an individualized patient treatment. Yttrium-90 glass microspheres are indicated for the treatment in early-stage HCC to the downstaging or bridging to liver transplantation or in patients with intermediate to advanced HCC. BCLC B patients refractory to transarterial chemoembolization (TACE) or BCLC C patients with branch portal vein thrombosis (PVT). Considering the favourable tumour response and long-term outcomes, this treatment is an option for unresectable HCC.

Keywords

HCC Radioembolization Dosimetry 

References

  1. 1.
    GLOBOCAN. Liver Cancer. Estimated incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp. Accessed 10 Sept 2015.
  2. 2.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRefGoogle Scholar
  3. 3.
    Atassi B, Bangash AK, Bahrani A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics. 2008;28(1):81–99.CrossRefPubMedGoogle Scholar
  4. 4.
    Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711.CrossRefPubMedGoogle Scholar
  5. 5.
    Yang T, Lau WY, Zhang H, et al. Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: surgeons’ perspective. World J Gastroenterol. 2015;21(27):8256–61.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Hepatobiliary cancers, V2.2015.Google Scholar
  7. 7.
    Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507.CrossRefPubMedGoogle Scholar
  8. 8.
    Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79(1):163–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192–201.CrossRefPubMedGoogle Scholar
  11. 11.
    Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741.CrossRefPubMedGoogle Scholar
  12. 12.
    Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium90 radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. Hepatology. 2013;57:1826–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718–38.  https://doi.org/10.1007/s00259-015-3068-8. (Epub 2015 Jun 27)CrossRefPubMedGoogle Scholar
  16. 16.
    Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.  https://doi.org/10.1007/s00259-013-2395-x.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Marco Maccauro
    • 1
  • Gianluca Aliberti
    • 1
  • Carlo Chiesa
    • 1
  • Carlo Spreafico
    • 2
  1. 1.Nuclear MedicineIstituto Nazionale Tumori (National Cancer Institute) IRCCS FoundationMilanItaly
  2. 2.Radiology 1Istituto Nazionale Tumori (National Cancer Institute) IRCCS FoundationMilanItaly

Personalised recommendations